Connect Biopharma Hldgs (CNTB) closed at $0.78 on November 2, 2026, down 3.1% from the previous close, on volume of 509,791 shares (30-day average 6,977,467).
Data as of November 2, 2026.
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha News (Thu, 29-Oct 3:44 PM ET)
3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
Globe Newswire (Wed, 30-Sep 10:22 AM ET)
CNTB jumps after Phase 2 COPD trial reports 100% reduction in return ED/hospital visits at one month
Market Chameleon (Wed, 30-Sep 5:51 AM ET)
Globe Newswire (Wed, 30-Sep 7:00 AM ET)
Market Chameleon (Wed, 16-Sep 7:05 AM ET)
Globe Newswire (Tue, 15-Sep 7:00 AM ET)
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Connect Biopharma Hldgs trades on the NASDAQ stock market under the symbol CNTB.
As of November 3, 2026, CNTB stock price was flat at $0.78 with 68,566 million shares trading.
CNTB has a beta of -1.16, meaning it tends to be less sensitive to market movements. CNTB has a correlation of 0.02 to the broad based SPY ETF.
CNTB has a market cap of $49.11 million. This is considered a Sub-Micro Cap stock.
Last quarter Connect Biopharma Hldgs reported $3 million in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.04.
In the last 3 years, CNTB traded as high as $3.82 and as low as $.51.
The top ETF exchange traded funds that CNTB belongs to (by Net Assets): IWM, VTWO, IWO, IWN, IWC.
CNTB has underperformed the market in the last year with a price return of -54.4% while the SPY ETF gained +11.7%. CNTB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -61.4% and -13.3%, respectively, while the SPY returned +1.2% and -1.6%, respectively.
CNTB support price is $.74 and resistance is $.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTB shares will trade within this expected range on the day.
